The Austin-based firm’s arrangement with Sanabil (Cayman) provides a $30 million senior unsecured revolving credit facility at a 7.00% fixed interest rate. Crucially, the deal avoids the common pitfalls of modern biotech financing: it requires no warrants, conversion features, or liens on the company’s intellectual property. For a firm built on proprietary biological data, shielding assets like source code and model weights from lenders remains a strategic priority.

CEO Jennifer Bath noted that the facility allows the company to fund its commercial build and biologics programs without issuing new shares. This shift in capital strategy comes at a time when industry peers are navigating diverse financial landscapes. While companies like Moderna are balancing credit draws with aggressive cost-cutting and Palantir maintains significant cash reserves, MindWalk’s structure aims to protect equity holders while the company matures its backloaded commercial revenue model. The agreement remains subject to the finalization of a definitive credit contract, though it underscores a growing trend of firms seeking alternative financing to maintain control over their core technology.